Table 1.
Lifetime discounted costs, effects and ICER before dominance principle applied.
| Interventions | Health Effects | Costs (USD) | ICER (Cost/QALY) | ||||
|---|---|---|---|---|---|---|---|
| LYGs | QALYs | Payer | Societal | Payer | Societal | ||
| Testing all BC patients | 14.164 | 13.483 | 4686 | 6808 | Testing all BC patients vs. testing based on FH/clinical criteria | 6848 | 4152 |
| Testing based on FH/clinical criteria | 14.149 | 13.470 | 4596 | 6753 | Testing all BC patients vs. no testing | 8340 | 5416 |
| No testing | 14.144 | 13.465 | 4554 | 6726 | - | - | - |
Abbreviations: BC, breast cancer; FH, family history; ICER, incremental cost-effectiveness ratio; LYG, life-years gained; QALY, quality-adjusted life-year.